Product manufacturers provide a lot of payments and items of value to doctors (all certainly out of the goodness of their hearts) says an analysis in JAMA.
Read More
A report from the Blue Cross Blue Shield Association condemns pricing of brand-name drugs as the major driver of drug spending growth.
Read More
A report from QuintilesIMS projects "moderate" growth in drug spending through 2021.
Read More
Twine Health entangles itself with more investors, stringing them along to get $1.5 million in new capital. We don't have enough health coaching vendors so that is what Twine's business is.
http://medcitynews.com/2017/05/twine-health-raising-1-5m/?utm_source=hs_email&utm_medium=email&utm_content=51576445&_hsenc=p2ANqtz-9qpN-tZ8uAuHXgIHIx3cgWUz_gvv92qjkzVl5Lt8bhQ3KwYkLTOHTWixtcHr8e5Rx2vzaJc6K1d12RwwHMneMYnV4cx1iJyd6XJ3RuvGaosiW9G6g&_hsmi=51576445&rf=1A study in the Journal of Health Economics finds that hospitals that merge are able to reduce costs, but payers and consumers don't see the benefits.
Read More
Research carried in JAMA reviews the effect of limiting drug rep interactions with physicians on prescriptions.
Read More
EverlyWell gets a lasting commitment of $5 million in fresh financing for its business of providing at-home lab test kits, which lead to "beautifully redesigned results". Not my words, the company's, who writes these things anyway, the figurative one million monkeys banging away on a keyboard.
http://www.businesswire.com/news/home/20170503005023/en/EverlyWell-Raises-Additional-Capital-Bringing-Total-5A study sponsored by the Health Care Cost Institute and published in Health Affairs looks at variation in prices paid by commercial health plans.
Read More